Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Cash Flow Quality Index
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Cash Flow Quality Index of -0.20x as of June 2023. Operating cash flow of €-64.53 Million is below net income of €321.70 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 2TZ cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Tianjin Zhong Xin Pharmaceutical Group C cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
Year-by-year earnings quality comparison for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited. For live market cap and the full company financial profile, see 2TZ stock market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | €461.07 Million | €2.13 Billion | ▼ -47.8% |
| 2024 | 0.41x | €924.67 Million | €2.23 Billion | ▼ -40.6% |
| 2023 | 0.70x | €688.49 Million | €986.71 Million | ▼ -11.2% |
| 2022 | 0.79x | €677.25 Million | €861.79 Million | ▼ -29.1% |
| 2021 | 1.11x | €852.40 Million | €769.14 Million | ▲ +9.2% |
| 2020 | 1.01x | €671.42 Million | €661.70 Million | ▲ +28.1% |
| 2019 | 0.79x | €495.49 Million | €625.57 Million | ▲ +27.1% |
| 2018 | 0.62x | €350.14 Million | €561.68 Million | ▲ +7570.7% |
| 2017 | -0.01x | €-3.97 Million | €476.08 Million | ▼ -100.8% |
| 2016 | 0.99x | €417.77 Million | €422.42 Million | ▲ +23.8% |
| 2015 | 0.80x | €360.58 Million | €451.44 Million | ▼ -0.4% |
| 2014 | 0.80x | €286.85 Million | €357.80 Million | ▲ +32.1% |
| 2013 | 0.61x | €213.44 Million | €351.79 Million | — |